STOCK TITAN

Igm Biosciences, Inc. - IGMS STOCK NEWS

Welcome to our dedicated page for Igm Biosciences news (Ticker: IGMS), a resource for investors and traders seeking the latest updates and insights on Igm Biosciences stock.

IGM Biosciences, Inc. (IGMS) is a clinical-stage biotechnology company pioneering IgM antibody therapeutics for cancer, autoimmune disorders, and inflammatory diseases. This page serves as the definitive source for official news, press releases, and financial updates directly from the company and verified partners.

Investors and stakeholders will find timely updates on clinical trial milestones, regulatory developments, and strategic collaborations with global pharmaceutical leaders. The curated content includes earnings reports, research breakthroughs, and pipeline advancements related to the company’s proprietary IgM platform, which enables multispecific antibody engineering.

Bookmark this page to track IGM Biosciences’ progress in developing novel therapies that leverage the unique binding capabilities of IgM antibodies. Visit regularly for unfiltered access to critical updates that may impact long-term investment strategies and sector analysis.

Rhea-AI Summary

IGM Biosciences, a clinical-stage biotechnology firm, will host a conference call and live audio webcast on December 5, 2020, at 2:00 p.m. ET. This event follows the first clinical data presentation of IGM-2323 from their Phase 1 trial at the 62nd American Society of Hematology Annual Meeting. Interested parties can access the call by dialing (866) 649-1996 or (409) 217-8769, using conference ID 1141638. The call will also be available via a live webcast on their website, with a replay accessible for 90 days afterward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
conferences
-
Rhea-AI Summary

IGM Biosciences, a clinical-stage biotechnology firm, announced that CEO Fred Schwarzer participated in a fireside chat ahead of the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. A recording of this discussion is accessible on the company’s website in the Investors section and will be available for 90 days. IGM Biosciences focuses on developing engineered IgM antibodies and has made significant advancements since 2010 in overcoming challenges related to their therapeutic use.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
conferences
-
Rhea-AI Summary

IGM Biosciences (Nasdaq: IGMS) announced that CEO Fred Schwarzer will present at three investor conferences in November 2020. The conferences are: Stifel Virtual Healthcare Conference on November 16 at 3:20 p.m. ET, Jefferies Virtual London Healthcare Conference on November 17 at 2:20 p.m. ET, and Wolfe Research Healthcare Conference on November 18 at 12:55 p.m. ET. A live webcast will be available on the company’s website, with replays accessible for 90 days after the events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.22%
Tags
conferences
Rhea-AI Summary

IGM Biosciences (Nasdaq: IGMS) reported its Q3 2020 results, showing a net loss of $20.3 million, or $0.66 per share, up from a loss of $10.2 million in Q3 2019. Cash and investments decreased to $180.2 million from $236.6 million at year-end 2019. Key updates include initial Phase 1 data presentation for IGM-2323 at the ASH Annual Meeting in December and the initiation of the Phase 1 trial for IGM-8444. IGM also announced a collaboration with AbCellera for novel IgM antibody discovery. The company anticipates 2020 operating expenses of $80-$85 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
-
Rhea-AI Summary

IGM Biosciences (Nasdaq: IGMS) announced the upcoming presentation of initial clinical data for IGM-2323 at the ASH Annual Meeting on December 5, 2020. This bispecific IgM antibody aims to target CD20 on lymphoma cells and CD3 on T cells, presenting a novel approach to treating non-Hodgkin’s lymphoma. The Phase 1 trial has shown positive initial findings, with no dose-limiting toxicities reported among eight patients treated. Preliminary results indicated favorable safety profiles and T cell activation, suggesting potential advantages over traditional therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
conferences clinical trial
-
Rhea-AI Summary

IGM Biosciences has announced the dosing of the first patient in its Phase 1 clinical trial for IGM-8444, an IgM antibody targeting the DR5 protein in solid cancers and non-Hodgkin’s lymphoma. This multicenter trial will assess the pharmacokinetics, safety, and preliminary efficacy of IGM-8444 as a monotherapy and in combination with chemotherapy. Initial data is expected in 2021. The trial signifies a key milestone for IGM, marking the second program from its IgM antibody platform to enter clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
Rhea-AI Summary

IGM Biosciences (Nasdaq: IGMS) has announced the dosing of its first patient in a Phase 1 clinical trial for IGM-8444, an IgM antibody targeting DR5 in patients with solid tumors and non-Hodgkin’s lymphoma. The trial aims to assess pharmacokinetics, safety, and preliminary efficacy of IGM-8444, both alone and with chemotherapy. Initial data is expected in 2021. CEO Fred Schwarzer noted the trial's significance as part of IGM's strategy utilizing its proprietary IgM technology platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
-
Rhea-AI Summary

AbCellera and IGM Biosciences (Nasdaq: IGMS) have announced a strategic research collaboration aimed at developing novel IgM antibodies. This multi-year agreement involves AbCellera creating antibody panels for various therapeutic targets identified by IGM, which will then have the rights to develop and commercialize these antibodies. Financial details remain undisclosed. IGM aims to leverage this partnership to enhance its IgM and IgA technology platform, potentially addressing challenges in current therapies. Leadership from both companies expressed optimism regarding the collaboration's impact on therapeutic advancements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
none
-
Rhea-AI Summary

IGM Biosciences, a clinical-stage biotechnology firm, announced that CEO Fred Schwarzer will present at four investor conferences in September 2020. The conferences include:

  • Baird 2020 Global Healthcare Conference on September 9 at 3:10 p.m. ET
  • H.C. Wainwright 22nd Annual Global Investment Conference on September 16 at 1:00 p.m. ET
  • 2020 Cantor Global Virtual Healthcare Conference on September 17 at 4:40 p.m. ET
  • Morgan Stanley 18th Annual Global Healthcare Conference on September 18 at 11:45 a.m. ET

Live webcasts will be available on the company's website with a 90-day archive.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.57%
Tags
conferences
Rhea-AI Summary

IGM Biosciences (Nasdaq: IGMS) announced significant advancements, including FDA clearance for its IND application for IGM-8444, aimed at treating solid and hematologic malignancies. The Phase 1 trial will assess its efficacy alongside chemotherapy. Additionally, Kathy Miller, Ph.D., has been appointed Vice President of Antibody Discovery. Financially, IGM reported a Q2 2020 net loss of $18.8 million, an increase from the previous year, with cash reserves decreasing to $203.1 million. The company's guidance for 2020 remains unchanged, anticipating $75-$85 million in non-GAAP operating expenses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
Igm Biosciences, Inc.

Nasdaq:IGMS

IGMS Rankings

IGMS Stock Data

72.93M
31.06M
38.81%
59.41%
1.93%
Biotechnology
Pharmaceutical Preparations
Link
United States
MOUNTAIN VIEW